Division of Shire PLC
Latest From Baxalta Inc.
Shire had a combined 17 manufacturing plants after the Baxalta merger, but plans to cut that to a total of 12. Manufacturing issues hit sales of its HAE drug Cinryze in the third quarter, and the firm is losing Lialda sales faster than expected.
Veteran biopharma deal-maker Mark Enyedy has a new role as CEO of ImmunoGen, currently an investor favorite – company shares are up nearly 200% this year. In this interview he discusses corporate restructuring, the evolving role of business development and making new scientific inroads against hard-to-treat cancers.
Halozyme CEO Helen Torley spoke with Scrip about execution of the company's strategy – reworked after her arrival in 2014 – to focus on oncology drug development and partnerships using its Enhanze platform.
The merger with Baxalta left Shire a portfolio consisting of 80% rare disease therapies, suggesting logically that the company might want to exit the primary care ADHD space.
- Gene Therapy, Cell Therapy
- Large Molecule
- Therapeutic Areas
- Blood & Coagulation Disorders & Products
- Immune Disorders
- Neurology, Nervous System
- Baxter BioScience
- North America
- Parent & Subsidiaries
- Shire PLC
- Senior Management
Ludwig N Hantson, PhD, Pres. & CEO
Robert J Hombach, EVP, CF & COO
John J Orloff, MD, EVP, Head, R&D & CSO
- Contact Info
Phone: (224) 940-2000
One Baxter Pkwy.
Deerfield, IL 60015
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.